Scholarlink

Background <p>Previous studies have shown that reducing drug-related problems (DRPs) may improve therapeutic outcomes in patients with Parkinson’s disease (PD).</p> Aim <p>To investigate the impact of pharmacist participation in Parkinson’s disease clinic on the number of DRPs, clinical outcomes, and the quality of life of PD patients.</p> Method <p>This single-blinded randomised controlled trial was conducted at the Parkinson’s Disease and Movement Disorders Clinic. Patients aged ≥ 18&#xa0;years, diagnosed with idiopathic PD for at least 3&#xa0;years, and receiving antiparkinsonian drugs were randomly assigned (1:1) to the pharmacist-physician (PP) or usual care (UC) groups. The primary outcome was changes in the number of DRPs from baseline to 24&#xa0;weeks between groups. Secondary outcomes included the Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) score, eight-item version of the Parkinson’s Disease Questionnaire (PDQ-8) score, and Patients’ Global Impression of Change (PGIC) score at week 24.</p> Results <p>A total of 80 patients were randomised, with 40 in each group. The mean number of DRPs reduced in both groups; however, the reduction was greater in the PP group compared to the UC group (− 7.2 ± 3.6 vs. − 3.0 ± 1.8, <i>p</i> &lt; 0.001), especially non-adherence issues. The MDS-UPDRS and PDQ-8 scores showed significantly greater improvement in the PP group. A higher proportion of patients in the PP group achieved improvement in PGIC scales compared to those in the UC group.</p> Conclusion <p>Our findings demonstrated that pharmacist-physician collaboration service in the PD clinic positively impacted patient outcomes.</p> Trial registration <p>ClinicalTrials.gov NCT05410210 (date 13 May 2022).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of pharmacist-physician collaboration on patient outcomes in Parkinson’s disease: a randomised controlled trial in tertiary care

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月13日

查看全文
  • Phanutgorn Techa-angkoon,
  • Yuvadee Pitakpatapee,
  • Weerawat Saengphatrachai,
  • Prachaya Srivanitchapoom,
  • Thanarat Suansanae

摘要

Background

Previous studies have shown that reducing drug-related problems (DRPs) may improve therapeutic outcomes in patients with Parkinson’s disease (PD).

Aim

To investigate the impact of pharmacist participation in Parkinson’s disease clinic on the number of DRPs, clinical outcomes, and the quality of life of PD patients.

Method

This single-blinded randomised controlled trial was conducted at the Parkinson’s Disease and Movement Disorders Clinic. Patients aged ≥ 18 years, diagnosed with idiopathic PD for at least 3 years, and receiving antiparkinsonian drugs were randomly assigned (1:1) to the pharmacist-physician (PP) or usual care (UC) groups. The primary outcome was changes in the number of DRPs from baseline to 24 weeks between groups. Secondary outcomes included the Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) score, eight-item version of the Parkinson’s Disease Questionnaire (PDQ-8) score, and Patients’ Global Impression of Change (PGIC) score at week 24.

Results

A total of 80 patients were randomised, with 40 in each group. The mean number of DRPs reduced in both groups; however, the reduction was greater in the PP group compared to the UC group (− 7.2 ± 3.6 vs. − 3.0 ± 1.8, p < 0.001), especially non-adherence issues. The MDS-UPDRS and PDQ-8 scores showed significantly greater improvement in the PP group. A higher proportion of patients in the PP group achieved improvement in PGIC scales compared to those in the UC group.

Conclusion

Our findings demonstrated that pharmacist-physician collaboration service in the PD clinic positively impacted patient outcomes.

Trial registration

ClinicalTrials.gov NCT05410210 (date 13 May 2022).